Loading organizations...
§ Private Profile · Vancouver, BC, Canada
Preclinical biotech develops LNP-mRNA therapies to deliver therapeutic proteins to the brain for neurological disorders.
CereCura is a Vancouver, British Columbia-based biotechnology company developing lipid nanoparticle-based messenger RNA therapies to deliver therapeutic proteins directly across the blood-brain barrier for the treatment of severe neurological disorders. The preclinical-stage biotech firm has secured $2.2 million in total equity financing, including an $800,000 pre-seed round and a $1.4 million seed round, alongside approximately $4 million in non-dilutive government grants. WUTIF Capital led the company's recent seed funding to advance its lead preclinical program targeting neuronopathic Gaucher disease, a rare genetic condition. The company's proprietary delivery platform builds upon the foundational lipid nanoparticle technology previously utilized in COVID-19 vaccines to address acute brain injuries and chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, and ALS. CereCura was officially founded in 2022 by Louis-Philippe Bernier, Nicholas Weilinger, Brian MacVicar, Pieter Cullis, and Richard Howlett.
CereCura has raised $1.0M across 1 funding round.
CereCura has raised $1.0M in total across 1 funding round.
CereCura has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in November 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 14, 2025 | $1M Seed | Aaron Stuart | E Fund, Entrepreneurship@ubc, Hextwo Capital | Announced |
CereCura has raised $1.0M in total across 1 funding round.
CereCura's investors include Aaron Stuart, E-Fund, entrepreneurship@UBC, Hextwo Capital.